Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA2NYS)

• Drug Name: Lampalizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Geographic retinal atrophy	9B78.9	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMA2NYS

Molecule-Related Drug Atlas

Drug(s) Targeting Complement factor D (CFD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALXN2040	DMLJ18Y	Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 3	[3]
ACH-4471	DMLVCZR	Anaemia	3A90	Phase 2	[4]
Vemircopan	DM3RZ9H	Generalized myasthenia gravis	8C60	Phase 2	[5]
Vemircopan	DM3RZ9H	Generalized myasthenia gravis	8C60	Phase 2	[6]
BCX-9930	DMBNC1I	Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 2	[7]
Anti-Factor D	DM8ENKS	Age-related macular degeneration	9B75.0	Phase 1/2	[8]
ALXN2080	DMQPZQB	Discovery agent	N.A.	Phase 1	[9]
example 373 [WO2012093101]	DMP8A5R	Discovery agent	N.A.	Investigative	[10]
HC3-1496	DM1BLCX	Autoimmune diabetes	5A10	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement factor D (CFD)	TT8D13I	CFAD_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02745119) Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT). U.S. National Institutes of Health.
• [2] In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95.
• [3] Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Dec 1;106(12):3188-3197.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of AstraZeneca
• [6] ClinicalTrials.gov (NCT04170023) A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT05116774) A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy. U.S.National Institutes of Health.
• [8] Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9.
• [9] Clinical pipeline report, company report or official report of Alexion
• [10] Factor D Inhibitors for the Treatment of AMD: Patent Highlight. ACS Med Chem Lett. 2012 Aug 27;3(10):781-2.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2842).